Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M3 receptors

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 3, 2013, Pages 323-333

  Deng, Huayun ^a   Sun, Haiyan ^a   Fang, Ye ^a  

^a Corning Incorporated ^*  (United States)

Author keywords

Biased agonism; Drug residence time; Dynamic mass redistribution; Efficacy; G protein coupled receptor; Muscarinic M3 receptor

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MUSCARINIC AGENT; MUSCARINIC M3 RECEPTOR;

ARTICLE; CELL ASSAY; CELL LINE; CELL STRAIN CCRF CEM; CELL STRAIN HCT 15; CELL STRAIN HT 29; CELL STRAIN PC 3; CELL STRAIN SF268; DRUG BIASED AGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DYNAMIC MASS REDISTRIBUTION ASSAY; HELA CELL; HUMAN; HUMAN CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WHOLE CELL;

BIASED AGONISM; DMR; DRUG RESIDENCE TIME; DYNAMIC MASS REDISTRIBUTION; EFFICACY; G PROTEIN-COUPLED RECEPTOR; GPCR; HANKS' BALANCED SALT SOLUTION; HBSS; MUSCARINIC M(3) RECEPTOR; REAL TIME POLYMERASE CHAIN REACTION; RESONANT WAVEGUIDE GRATING; RT-PCR; RWG;

CELL LINE; CELL LINE, TUMOR; HUMANS; LIGANDS; MUSCARINIC AGONISTS; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, MUSCARINIC M3; RECEPTORS, G-PROTEIN-COUPLED; TIME FACTORS;

EID: 84883344244     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.07.005     Document Type: Article

References (54)

1. Black J.W., Leff P. Operational models of pharmacological agonism. Proceedings of the Royal Society B: Biological Sciences 1983, 220:141-162.
2. Boehr D.D., Nussinov R., Wright P.E. The role of dynamic conformational ensembles in biomolecular recognition. Nature Chemical Biology 2009, 5:789-796.
3. Calebiro D., Nikolaev V.O., Persani L., Lohse M.J. Signaling by internalized G-protein-coupled receptors. Trends in Pharmacological Sciences 2010, 31:221-228.
4. Casarosa P., Bouyssou T., Germeyer S., Schnapp A., Gantner F., Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. The Journal of Pharmacology and Experimental Therapeutics 2009, 330:660-668.
5. Caulfield M.P., Birdsall N.J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacological Reviews 1998, 50:279-290.
6. Charlton S.J. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. British Journal of Pharmacology 2009, 158:165-168.
7. Copeland R.A., Pompliano D.L., Meek T.D. Drug-target residence time and its implications for lead optimization. Nature Reviews Drug Discovery 2006, 5:730-739.
8. 3 receptor antagonists with label-free whole-cell assays. Analytical Chemistry 2012, 84:8232-8239.
9. Fang Y. Label-free receptor assays. Drug Discovery Today: Technologies 2010, 7:e5-e11.
10. Fang Y. The development of label-free cellular assays for drug discovery. Expert Opinion on Drug Discovery 2011, 6:1285-1298.
11. Fang Y. Ligand-receptor interaction platforms and their applications for drug discovery. Expert Opinion on Drug Discovery 2012, 7:969-988.
12. Fang Y. Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. Journal of Pharmacological and Toxicological Methods 2013, 67:69-81.
13. Fang Y., Ferrie A.M., Fontaine N.H., Mauro J., Balakrishnan J. Resonant waveguide grating biosensor for living cell sensing. Biophysical Journal 2006, 91:1925-1940.
14. Fang Y., Frutos A.G., Verklereen R. Label-free cell-based assays for GPCR screening. Combinatorial Chemistry & High Throughput Screening 2008, 11:357-369.
15. Fang Y., Li G., Ferrie A.M. Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells. Journal of Pharmacological and Toxicological Methods 2007, 55:314-322.
16. 2 receptor signaling in A431 cells. FEBS Letters 2005, 579:6365-6374.
17. Felder C.C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. The FASEB Journal 1995, 9:619-625.
18. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Molecular Pharmacology 2006, 70:1575-1584.
19. 2-adrenergic receptor. PLoS One 2011, 6:e19282.
20. Goral V., Wu Q., Sun H., Fang Y. Label-free optical biosensor with microfluidics for sensing ligand-directed functional selectivity on trafficking of thrombin receptor. FEBS Letters 2011, 585:1054-1060.
21. Guo D., Mulder-Krieger T., Ijzerman A.P., Heitman L.H. Functional efficacy of adenosine A[U+2082]A receptor agonists is positively correlated to their receptor residence time. British Journal of Pharmacology 2012, 166:1846-1959.
22. 2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide. Molecular Pharmacology 2005, 68:769-778.
23. Jakubik J., Janickova H., Randakova A., Ei-Fakahany E.E., Dolezal V. Subtype differences in pre-coupling of muscarinic acetylcholine receptors. PLoS One 2011, 6:e27732.
24. 2-adrenergic receptor. Nature Chemical Biology 2011, 7:692-700.
25. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nature Reviews Drug Discovery 2005, 4:919-927.
26. Kenakin T. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect. ACS Chemical Biology 2009, 4:249-260.
27. Kenakin T. The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacology & Toxicology 2012, 13:3.
28. Kenakin T. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. British Journal of Pharmacology 2013, 168:554-575.
29. Kenakin T., Miller L.J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacological Reviews 2010, 62:265-304.
30. Kholodenko B.N. Cell-signalling dynamics in time and space. Nature Reviews Molecular Cell Biology 2006, 7:165-176.
31. 3 receptors coupled to phosphoinositide metabolism. European Journal of Pharmacology 1989, 172:397-405.
32. Li G., Ferrie A.M., Fang Y. Label-free profiling of ligands for endogenous GPCRs using a cell-based high-throughput screening technology. Journal of the Association for Laboratory Automation 2006, 11:181-187.
33. 19F-NMR. Science 2012, 335:1106-1110.
34. Lohse M.J., Nikolaev V.O., Hein P., Hoffmann C., Vilardaga J.P., Bunemann M. Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. Trends in Pharmacological Sciences 2008, 29:159-165.
35. Lu H., Tonge P.J. Drug-target residence time: critical information for lead optimization. Current Opinion in Chemical Biology 2010, 14:467-474.
36. 1 receptor-G protein coupling in cell proliferation in the prostate. Life Sciences 1997, 60:963-968.
37. Mitchelson F.J. The pharmacology of McN-A-343. Pharmacology & Therapeutics 2012, 135:216-245.
38. 3 receptor coupling and regulation. Life Sciences 1997, 60:1039-1045.
39. Neves S.R., Ram P.T., Iyengar R. G protein pathways. Science 2002, 296:1636-1639.
40. Nginamau E.S., Maehle B.O., Jonsson R. An experimental protocol for the fractionation and 2DE separation of HeLa and A-253 cell lysates suitable for the identification of the individual antigenic proteome in Sjögren's syndrome. Autoimmunity 2011, 44:652-663.
41. Onaran H.O., Costa T. Where have all the active receptor states gone?. Nature Chemical Biology 2012, 8:674-677.
42. q heterotrimers. Nature Chemical Biology 2011, 7:740-747.
43. Sauliere A., Bellot M., Paris H., Denis C., Finana F., Hansen J.T., et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nature Chemical Biology 2012, 8:622-630.
44. Schröder R., Janssen N., Schmidt J., Kebig A., Merten N., Hennen S., et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nature Biotechnology 2010, 28:943-949.
45. Singh J., Petter R.C., Baillie T.A., Whitty A. The resurgence of covalent drugs. Nature Reviews Drug Discovery 2011, 10:307-317.
46. Swinney D.C. Biochemical mechanisms of drug action: what does it take for success?. Nature Reviews Drug Discovery 2004, 3:801-808.
47. Swinney D.C. Molecular mechanism of action (MMoA) in drug discovery. Annual Review of Medicinal Chemistry 2011, 46:301-317.
48. 3 receptor. Molecular Pharmacology 2009, 76:543-551.
49. Tran E., Fang Y. Duplexed label-free G protein-coupled receptor assays for high-throughput screening. Journal of Biomolecular Screening 2008, 13:975-985.
50. Valant C., Gregory K.J., Hall N.E., Scammells P.J., Lew M.J., Sexton P.M., et al. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. Journal of Biological Chemistry 2008, 283:29312-29321.
51. Verrier F., An S., Ferrie A.M., Sun H., Kyoung M., Deng H., et al. GPCRs regulate the assembly of a multienzyme complex for purine biosynthesis. Nature Chemical Biology 2011, 7:909-915.
52. 2 production in colon cancer cells. Carcinogenesis 2000, 21:1789-1793.
53. 2+ signaling to mAChR agonist in human leukemic T cell line CCRF-CEM (CEM) by reduction of response in small interfering RNA (siRNA)-treated cells. Journal of Pharmacological Sciences 2005, 97(Supplement 1):126.
54. Zhang R., Monsma F. The importance of drug-target residence time. Current Opinion in Drug Discovery & Development 2009, 12:488-496.